Bicara Therapeutics
(NASDAQ) BCAX
Bicara Therapeutics Financials at a Glance
Market Cap
$1.38B
Revenue (TTM)
$0.00
Net Income (TTM)
$137.95M
EPS (TTM)
$-2.52
P/E Ratio
-8.37
Dividend
$0.00
Beta (Volatility)
1.71 (High)
Dividend
$0.00
Beta (Volatility)
1.71 (High)
Price
$21.18
Volume
30,482
Open
$21.71
Price
$21.18
Volume
30,482
Open
$21.71
Previous Close
$21.18
Daily Range
$21.09 - $21.79
52-Week Range
$7.80 - $22.01
Dividend
$0.00
Beta (Volatility)
1.71 (High)
Price
$21.18
Volume
30,482
Open
$21.71
Previous Close
$21.18
Daily Range
$21.09 - $21.79
52-Week Range
$7.80 - $22.01
BCAX News
BCAX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Bicara Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
103
CEO
Claire Mazumdar, PhD, MBA
Website
www.bicara.comHeadquarters
Boston, MA 02116, US
BCAX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-31%
Return on Capital
-39%
Return on Assets
-32%
Earnings Yield
-11.95%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.38B
Shares Outstanding
65.47M
Volume
30.48K
Short Interest
0.00%
Avg. Volume
537.86K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$155.60M
EBITDA
$155.60M
Operating Cash Flow
$106.83M
Capital Expenditure
$280.00K
Free Cash Flow
$107.11M
Cash & ST Invst.
$414.80M
Total Debt
$1.71M
Bicara Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.38B
N/A
Market Cap/Employee
$25.14M
N/A
Employees
55
N/A
Net Income
$37.39M
-78.4%
EBITDA
$41.12M
-54.5%
Quarterly Fundamentals
Net Cash
$413.09M
-15.5%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$593.00K
+352.7%
Short Term Debt
$1.12M
+84.0%
Return on Assets
-32.01%
N/A
Return on Invested Capital
-38.70%
N/A
Free Cash Flow
$24.12M
+19.8%
Operating Cash Flow
$23.89M
+20.5%